Sadaf, Alina
Dong, Min
Pfeiffer, Amanda
Latham, Teresa
Kalfa, Theodosia
Vinks, Alexander A.
Ware, Russell E.
Quinn, Charles T. http://orcid.org/0000-0002-2372-2175
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Population Pharmacokinetic Analysis of l-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects
https://doi.org/10.1007/s40262-024-01349-4
Funding for this research was provided by:
Emmaus Medical, Inc.
Article History
Accepted: 23 January 2024
First Online: 24 February 2024
Declarations
:
: This research was supported by funding from Emmaus Medical, Inc., the manufacturer of Endari<sup>®</sup> (<scp>l-</scp>glutamine powder).
: Alina Sadaf, Min Dong, Amanda Pfeiffer, Teresa Latham, Theodosia Kalfa, Alexander A. Vinks, Russell E. Ware, and Charles T. Quinn have no conflicts of interest that are directly relevant to the content of this article.
: The Cincinnati Children’s Hospital Medical Center Institutional Review Board approved this study, and it was conducted according to the guidelines of the Declaration of Helsinki and the International Conference on Harmonisation.
: Adult participants provided written informed consent. Minors provided written assent, and their legal guardians provided written permission.
: Not applicable.
: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: Concept and planning of the study: AS, MD, AP, TSL, TAK, AAV, REW, CTQ. Acquisition, analysis, and interpretation of data: AS, MD, AP, TSL, TAK, AAV, REW, CTQ. Drafting and/or critical revision of the manuscript: AS, MD, REW, CTQ. Approval of the final submitted version of the manuscript: AS, MD, AP, TSL, TAK, AAV, REW, CTQ.